New drug aims to keep esophageal cancer at bay after standard treatment
NCT ID NCT04494009
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study tests whether a drug called INCMGA00012 (a PD-1 inhibitor) can help prevent esophageal cancer from returning after patients have completed chemoradiation. About 110 adults with locally advanced esophageal squamous cell carcinoma will be randomly assigned to receive the drug or just be observed. The goal is to see if the drug extends the time before the cancer grows back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
Conditions
Explore the condition pages connected to this study.